NEW YORK (GenomeWeb News) – Omicia said today that it intends to use funds from a recently closed $6.8 million Series A financing round led by Artis Ventures to expand its marketing reach and to optimize its whole-genome interpretation offering.

Other investors in the round included Acadia Woods Partners, Bay City Capital, Buchanan Investments, and Casdin Capital. As part of their investment, Tad Buchanan, principal of Buchanan Investments, and William Gerber from Bay City Capital will also join Omicia's board of directors, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.